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Pathogenesis of psoriasis involves the keratinocytes in epidermis as well as the angiogenesis involving deeper
skin layers. So, the drug delivery strategy should be customized to localize paclitaxel (PCL) inside both layers. In
this investigation, in order to achieve penetration of PCL into deeper skin layers while minimizing the systemic
escape, a nanoemulsion (NE) was formulated and evaluated its in vivo pharmacokinetic performance. Further,
the same formulation was explored for peroral bioavailability enhancement of PCL. Upon dermal application,
the drug was predominantly localized in deeper skin layers, with minimal systemic escape. When orally
administered as NE, PCL was rapidly absorbed reaching a steady-state value of 3.5 mg/ml in 30 minutes, and
steady-state levels persisted up to 18 hours. This has amounted to an absolute bioavailability of 70.62%.
Inhibition of P-glycoprotein efflux by D-a-tocopheryl polyethyleneglycol 1,000 succinate and labrasol would
have contributed to the enhanced peroral bioavailability of PCL. This investigation provides direct evidence on
the localization of large molecular weight, lipophilic drug, PCL, in dermis. Further, the NE formulation has
enhanced the peroral bioavailability significantly to more than 70%. The developed NE formulation was safe and
effective for both peroral and dermal delivery of PCL.
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INTRODUCTION
Paclitaxel (PCL), a novel antineoplastic agent with unique
molecular mechanism of action, is active clinically against
advanced ovarian and breast cancer, and is under investiga-
tion for therapy of various cancers (Straubinger, 1995).
Although it is therapeutically very effective, its poor
biopharmaceutical properties severely limit its clinical usage.
PCL, being a poorly soluble and poorly permeable drug, is
classified under class IV of Biopharmaceutic Classification
System (BCS) (Kasim et al., 2003). It is currently administered
by infusion of ethanolic solution containing Cremophor EL
diluted in intravenous (i.v.) fluids. However, the presence of
Cremophor EL is reported to be responsible for many of the
adverse reactions of formulation (Gelderblom et al., 2001).
Therefore, to prepare Cremophor-free formulations for PCL
administration, many alternative formulation approaches
such as liposomes (Straubinger et al., 1993; Dhanikula and
Panchagnula, 2005a), mixed micelles (Alkan-Onyuksel et al.,
1994), and microemulsions (He et al., 2003) were proposed.
Apart from solubility, PCL, being a P-glycoprotein (P-gp)
substrate (Varma and Panchagnula, 2005), oral bioavail-
ability is very poor. Approaches to overcome poor oral
bioavailability have received limited success so far (Sparre-
boom et al., 1997; Kimura et al., 2002; Woo et al., 2003),
prompting a clear need to develop PCL for administration by
alternative routes using Cremophor-free formulations.
Previously, the regional pharmacokinetic advantage of
PCL localized delivery was demonstrated (Dhanikula and
Panchagnula, 1999, 2004; Dhanikula et al., 2005b). Enhanc-
ing local levels of drug at therapeutic target, while keeping
the systemic drug concentrations low will help in the treat-
ment of diseases such as psoriasis and melanoma, against
which PCL is pharmacologically effective (Amato et al.,
1998; Lee et al., 1998; Kunstfeld et al., 2003), but clinically
limited owing to poor distribution into skin layers. Dermal
drug delivery systems are designed to obtain a local effect in
the desired skin layer upon their application on skin surface.
Hence, they are intended to localize maximum drug con-
centration in skin layer of interest with a minimum net drug
transport across skin (Behl et al., 1993). Therefore, during
pharmacokinetic evaluation of dermal delivery systems,
the dosage from performance has to be viewed from two
aspects: efficacy (dermal bioavailability) and systemic safety
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(percutaneous absorption owing to drug escape). The
disposition of drug, once it crosses stratum corneum (SC), is
a complex process. It can be made to cross SC and localize in
the epidermis and dermis with formulation approach such as
by using skin depot formers, or by using vesicles and nano-
emulsions (NEs). Further, PCL with high molecular weight
(MW) (853.9 Da) and lipophilicity (Log P 3.5) (Dhanikula and
Panchagnula, 1999) would not be taken up efficiently by
systemic circulation owing to poor rate of dissolution in the
scanty intercellular fluid as well as lesser diffusion coefficient
by virtue of high MW. This will lead to the formation of depot
in the deeper skin layers, leading to high local drug
concentrations coupled with minimum systemic escape.
NEs are thermodynamically stabilized dispersions of oil in
water (Tenjarla, 1999). These novel formulations enhance
drug delivery into and across skin primarily by increasing
concentration gradient across skin (Kreilgaard, 2002a). NEs
also perturb the skin barrier function by virtue of the presence
of surfactants, which are well-known penetration enhancers
(Kreilgaard, 2002a, b).
As pathogenesis of psoriasis involves the keratinocytes in the
epidermis (Frye et al., 2003) as well as the angiogenesis
involving deeper skin layers (Kunstfeld et al., 2003), the drug
delivery strategy should be customized to localize PCL
concentrations inside these two layers. However, PCL being a
large molecule (853.3 Da), the deep skin penetration is very
difficult. Previously, we demonstrated that skin bilayer alter-
ation alone is not sufficient to enhance the transdermal per-
meation of PCL (Panchagnula et al., 2005). In this investigation,
in order to achieve penetration of PCL into deep skin layers
while minimizing the systemic escape, NEs were formulated
and evaluated for their in vivo drug delivery performance.
Further, the same NEs were evaluated for oral bioavailability
enhancement as well. All excipients used in the formulation of
NEs are approved for peroral drug delivery (Table 1).
RESULTS AND DISCUSSION
Physical characteristics of formulation
Physical characteristics of formulation are summarized in
Table 2. The formulation was infinitely dilutable without any
phase separation. It has showed a nanoglobule size
(21.58 nm), with minimal size distribution (poly dispersity
index 0.13), and zeta potential approaching zero. The
globule size and polydispersity increased slightly to
41.7 nm and 0.2037, respectively, upon infinite dilution,
but still remained in nanosize range. No large volume
fraction or liquid crystalline phases were observed, until
infinite dilution of formulation.
Pharmacokinetics of PCL in Sprague–Dawley rats
In order to assess the absolute bioavailability of PCL from
different routes of administration using NE, initially the i.v.
pharmacokinetic parameters were determined. PCL showed
a two-compartment disposition upon i.v. administration
(Figure 1). Plasma concentration of PCL had declined in a
bi-exponential manner from peak concentration of 35 mg/ml
to zero in 12 hours. Hence, the concentration profile was
analyzed by two-compartment model using PCNONLIN.
Typical of a lipophilic molecule, PCL has rapidly distri-
buted (a half-life: 0.4152 hours) and then eliminated slowly
Table 1. Composition of PCL formulations tested in vivo
Component Formulation I (blank) Formulation II1 (Taxol) Formulation III2 (nanoemulsion)
Labrasol+vitamin E-TPGS (3:1) 480 mg — 1,920 mg
Labrafil M1944CS 20 mg — 80 mg
Paclitaxel — 20 mg 20 mg
14C-paclitaxel — 1 mCi 1 mCi
Cremophor EL — 1,676.5 mg —
Ethanol — 1,244.7 mg —
Routes of administration Dermal i.v. (10 mg/kg), Oral (10 mg/kg) Dermal (8 mg/kg), oral (10 mg/kg)
i.v., intravenous; NE, nanoemulsion; PCL, paclitaxel; TPGS, D-a-tocopheryl polyethyleneglycol 1,000 succinate.
i.v. administration was performed to assess pharmacokinetic parameters and absolute bioavailability.
1Formulation II (Taxol) was prepared in the laboratory using the procedure and formula reported previously (Gao et al., 2003).
2For oral administration, the NE formulation was compared with Taxol. Only NE is applied dermally as patch and compared with blank formulation patch
and occlusion control for any potential irritancy.
Table 2. The screening summary of formulation1
Character Remarks
Dilution potential E100%
Effect of dilution Stable till infinity
Globule size (z-ave) (nm) 21.58
Polydispersity index 0.13
Zeta potential (mV) 0.2170.54
Globule size at infinite dilution (nm) 41.71
Polydispersity index at infinite
dilution
0.21
Polarized light microscopy Clear at original
magnification  630
pH 3.44
The values are expressed as mean7SEM.
The physical characterization was performed in triplicate.
1Composition of formulation is described in Table 1.
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(b half-life: 3.0924 hours). The dose-independent pharmaco-
kinetic parameters determined were in agreement with the
values reported earlier (Gao et al., 2003; He et al., 2003)
(Table 3). The area under the curve (AUC)0N upon i.v.
administration was used as reference to calculate the
absolute bioavailability from oral and dermal administration
of PCL. Non-linearity in pharmacokinetics of PCL was
reported earlier in the range of 2–20 mg/kg (Gelderblom et al.,
2001). For that reason, formulations administered by different
routes were compared at same dose of PCL (10 mg/kg).
Oral bioavailability enhancement of PCL using NE formulation
Upon oral administration of marketed Taxol formulation,
owing to poor peroral absorption, plasma levels charac-
teristically remained below 300 ng/ml (Figure 2), and the
absolute bioavailability, calculated on the basis of AUC0N,
was 10.62% (Figure 3). In contrast, PCL delivered from NE100
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Figure 1. i.v. plasma concentration profile** of PCL administered via
femoral vein (10 mg/kg). Taxol formulation was injected through femoral vein
over a period of 3 minutes. The drug showed two-compartment disposition
characterized by rapid distribution followed by slow elimination. The
dose-independent parameters correlated well with literature reports
(Gao et al., 2003; He et al., 2003). The AUC24N was calculated from
formula C24/b, and AUC0N¼AUC0–24þAUC24N. **This profile is the
mean7SEM of 4–5 Sprague–Dawley rats.
Table 3. i.v. pharmacokinetic parameter of PCL
administered as Taxol (10 mg/kg)
Parameter Units Magnitude
A mg/ml 25.98
B mg/ml 14.91
a h1 1.6692
b h1 0.2241
AUC0-N mg/ml h 85.84
K10 h
1 0.4981
K12 h
1 0.6441
K21 h
1 0.7511
Vd ml 61.13
Cltotal ml/h 30.44
AUMC mg/ml h2 306.22
MRT h 3.73
AUC, area under the curve; AUMC, area under first moment plasma con-
centration; i.v., intravenous; MRT, mean residence time; PCL, paclitaxel.
The AUC0t was calculated using linear trapezoidal rule and AUCtN
was estimated from Ct/Kel, then by adding these two components,
AUC0-N was calculated. Vd – volume of distribution and Cltotal – total
plasma clearance rate are dose-independent pharmacokinetic parameters
and dependent on physiology and drug molecule. AUMC is the area
under first moment plasma concentration–time profile, and MRT (mean
residence time) is the ratio of AUMC and AUC.
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Figure 2. Plasma concentration profile of PCL when administered orally as
NE and its comparison with i.v. and oral Taxol. The inset graph is the
magnified bottom portion in order to show clearly the plasma drug
concentrations obtained by non-i.v. routes. Oral NE and Taxol plasma
concentrations are mean7SEM of six rats, i.v. profile is the mean7SEM of 4–5
rats, whereas the dermal application profile is expressed as mean7SEM of
four rats. NE formulation (coded as LMEV_24 in text) containing TPGS as
co-surfactant was administered by various routes to calculate relative and
absolute bioavailability. PCL formulation commercially available as Taxol,
containing Cremophor EL and dehydrated ethanol was used as reference
formulation. Oral absolute bioavailability of PCL was very low (10.62%) and
improved seven times (70.25%), when administered as NE. PCL was
administered at 10 mg/kg dose orally and intravenously. Dermally it was
administered at 8 mg/kg dose. As it is a case of infinite dosing, and rate control
is with skin, the amount of applied dose is not significant.
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Figure 3. The absolute bioavailability of PCL administered from various
formulation via different routes of administration. The numbers indicate the
absolute bioavailability of formulations. The absolute bioavailability was
calculated from the ratio of AUC0N of each formulation with that obtained
upon i.v. administration of same dose of PCL.
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was rapidly absorbed reaching a steady-state value of 3.5mg/ml
in 30 minutes, and steady-state levels persisted up to
18 hours. This has amounted to an absolute bioavailability
of 70.62% (calculated on the basis of AUC0N). Such a high
extent of oral bioavaliabilty is remarkable in light of the fact
that, although many reports on formulations with improved
oral bioavailability of PCL were published, none had shown
above 30% absolute bioavailability (Kimura et al., 2002;
Gao et al., 2003; Woo et al., 2003). Another interesting
observation is the persistence of plasma drug concentrations
from 0.5 to 18 hours at 3mg/ml (Figure 2, inset), suggesting
that drug is absorbed through out the gastrointestinal track.
Significant amount of drug was absorbed from distal
gastrointestinal track as well (ileum and colon), where
gastrointestinal transit time lasts from 4 to 24 hours. Owing
to the fact that P-gp expression is high in this area of
gastrointestinal track, especially ileum, its absorption could
not be enabled without the inhibition of P-gp by D-a-
tocopheryl polyethyleneglycol 1,000 succinate (TPGS) and
labrasol (LSOL).
P-gp is a membrane transporter that actively pumps
xenobiotics out of cells. Given the very broad specificity of
P-gp, its activity in the intestine can reduce the oral
bioavailability of a wide range of drugs. PCL oral bioavail-
ability has been reported to be mainly limited by the P-gp-
mediated efflux (Sparreboom et al., 1997; Dintaman and
Silverman, 1999; Kimura et al., 2002; Varma et al., 2003;
Woo et al., 2003). Many surfactants and excipients have been
shown to inhibit P-gp, and thus potentially enhance drug
absorption. Excipients including LSOL and TPGS were
reported to inhibit P-gp, thus enhancing the permeation of
digoxin, a known P-gp substrate, using everted gut sac model
(Cornaire et al., 2004). TPGS increased the absorption flux of
amprenavir (Yu et al., 1999), and has been characterized as
an inhibitor of P-gp-mediated drug transport in the human
intestinal Caco-2 cell monolayers and other cell lines
(Dintaman and Silverman, 1999; Bogman et al., 2003). It
has been shown to enhance the bioavailability of cyclospor-
ine in human volunteers (Chang et al., 2005) and of
colchicine in rats (Bittner et al., 2005). Recently, improved
intestinal absorption of macromolecular hydrophilic drug
vancomycin hydrochloride was reported using formulations
containing LSOL and TPGS (Prasad et al., 2003).
Further, excipients used in all formulations were approved
for oral use. LSOL, chemically containing caprylocaproyl
macrogol-8 glycerides, is official in European Pharmaco-
poeia, and approved for oral use. Its lethal dose (LD)50 is
reported to be as high as 22 g/kg in rats. TPGS is an oral
dietary supplement of vitamin E, and is reported to be non-
toxic with an acute LD50 of more than 7 g/kg in rats (Wu and
Hopkins, 1999). The oil, M1944, chemically known as oleoyl
macrogol-6 glycerides, also is orally approved excipient, and
is listed in European Pharmacopoeia.
Penetration and permeation of PCL upon dermal application of
NE formulation
In order to facilitate application of correct dose of formula-
tion, and control area of application, the NE was incorpo-
rated into a prototype patch and applied on dorsal skin of rat
using a medical grade adhesive. Before application of the
patch, it is necessary to ensure that patch does not control the
release of drug from formulation. Therefore, drug release was
evaluated from the patch using US Pharmacopeia 6 type
dissolution method. PCL release from dermal patch of 4 cm2
area showed complete release in 6 hours, of which 75%
occurred within 3 hours (data not shown). As a result, patch
was not expected to be rate controlling, and permeation was
controlled by skin itself.
Upon dermal application, the drug was predominantly
localized in different layers of skin, with minimal systemic
escape. By i.v. route, peak plasma concentrations reached up
to 35 mg/ml, and concentrations in different layers of skin
were in the range of 1 mg/4 cm2 (Figure 4). On the contrary,
upon dermal administration, even up to 48 hours drug
concentrations were below 100 ng/ml, as a result systemic
bioavailability reduced to mere 3.19% (Figure 3). Such
differential distribution of drug represents an excellent degree
of passive targeting to the tissue of interest, that is, the
epidermis and dermis, and satisfies the objective of mini-
mizing systemic escape, thereby effectively reducing body
burden, simultaneously maximizing local concentrations.
Distribution of drug into different skin layers and its variation
with time is depicted in Figure 4. Local concentration of PCL
in SC was around 0.5 mg till 4 hours. However, in effective
dose and live dermis, levels reached up to 4 and 10 mg,
respectively, by 4 hours. PCL is redistributed into different
layers and the equilibrium levels persisted at 3 and 7 mg,
respectively, in the epidermis and live dermis till 48 hours.
Concentration gradient for maintaining this equilibrium is
supplied by a high concentration of drug in SC. For the
purpose of dosing, based on ex vivo lag time for steady state
(5 hours) and the time to reach peak levels of drug in the
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Figure 4. Distribution of PCL. Distribution of PCL into different layers of skin
upon dermal administration as patch against systemic administration by i.v.
route, showing regional pharmacokinetic advantage of localized delivery
when compared to systemic delivery. Forty-eight hours data represent the
mean7SEM of four replicates, whereas at 1 hour and 4 hours, one animal
each was killed to obtain tissue distribution of drug. In case of i.v. dosing,
each bar is the mean7SEM of four replicates. Upon i.v. administration, drug
distribution is uniform in all skin layers at 1 mg/4 cm2, whereas peak systemic
concentration is 35mg/ml. On the contrary, upon dermal application,
maximum local concentration in live dermis layer reached to 10 mg, whereas
systemic concentrations were below 100 ng/ml. This proves the regional
pharmacokinetic advantage of these NEs when compared to systemic
administration for the therapy of diseases involving the skin.
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epidermis and live dermis, application of formulation for
4 hours would be sufficient.
Further, mass balancing indicated (Table 4) that upon i.v.
administration, 11.7% of drug is distributed into skin tissues,
14.9% remained in plasma compartment, and remaining
drug is distributed to other tissues. Whereas upon dermal
administration, total formulation bioavailability was observed
to be 6.2%, of which dermal bioavailability was 5.95% and
systemic bioavailability was mere 0.22%. This clearly proves
that drug is confined to skin layers without any systemic
escape.
When a drug molecule crosses SC and enters into the live
epidermis and dermis, its fate can follow one of the following
paths based on its inherent properties:
K Taken up by blood vessels to distribute into systemic
circulation.
K Get metabolized by enzymes.
K Localize there owing to poor aqueous solubility and
diffusion coefficient.
K Directly penetrate into deeper tissues such as adipose
tissue as well as muscle.
Among these pathways, first three are generally accepted,
but there is controversy regarding the actual depth and
quantity of drugs delivered to the local subcutaneous
structures after topical administration. Some initial reports
suggested that distribution of topically applied drug sub-
stances to underlying tissues occur mainly through systemic
blood supply and direct penetration, if present at all, is
minimal (Dawson et al., 1988; Radermacher et al., 1991).
However, contrary to the accepted concept, the blood supply
to the dermis is not capable of resorbing certain chemicals
proportionately to their penetration through the epidermis.
Consequently, local deep penetration of a series of lipophilic
pesticides and steroids was demonstrated in mice and rats
(Marty et al., 1989), and salicylate salt localization was
demonstrated in pigs (Baldwin et al., 1984). Singh and
Roberts (1996) have proposed structure–deep tissue penetra-
tion relationships for drugs with diverse physicochemical
properties. Apparently, the concentration of any solute in a
given tissue was dependent on concentration in preceding
tissue, implying that direct redistribution is essentially
concentration gradient driven. Further, the deep tissue
penetration of drugs when applied from aqueous solution
was greater for smaller solutes with adequate lipophilicity.
Higaki et al. (2002) proposed a six-compartment pharmaco-
kinetic model to explain the redistribution of drugs into
deeper tissues when applied topically. From among the
pharmacokinetic parameters analyzed, the clearance from
viable skin to the muscle was found to correlate directly to
the unbound drug fraction in viable skin, implying that the
larger amount of unbound drug in viable skin significantly
contributes to the direct penetration into muscle, rather than
into systemic circulation.
To summarize, the dermal delivery of a high MW and
lipophilic drug, owing to a combination of two adverse
physicochemical properties, could not be enhanced using
conventional penetration enhancers as well as vehicles
(Panchagnula et al., 2004a, 2005). Therefore, a combination
strategy involving penetration enhancement per se using lipid
bilayer alteration, along with enhanced concentration gra-
dient and improved partitioning into skin, was proposed. The
NEs have provided a custom-made opportunity to apply all
these combinations in one formulation. PCL has indeed
penetrated into the deeper skin layers up to subcutaneous
tissue. PCL has penetrated within 4 hours, and maintained its
high local concentration in respective skin layers up to
48 hours, with minimal redistribution. The reason behind the
successful localization of drug in deep skin layers is owing to
a combination of physicochemical properties of molecule as
well as the selective calibration of penetration–permeation
balance by the formulation. PCL penetration was enhanced
using improved solubilization in vehicle, where PCL is
expected to be at maximum thermodynamic activity, thus
enabling a high concentration gradient across the skin along
with improved partitioning and lipid bilayer perturbation
using a combination of surfactant penetration enhancers.
Surfactants are known skin penetration enhancers. They
either alone or in the form of microemulsions or niosomes
were reported to enhance skin permeation of drugs by
enhancing skin permeability and solubility (Kreilgaard,
2002b; Nokhodchi et al., 2003). Vaddi et al. (2001) had
attributed the skin penetration enhancement of haloperidol
Table 4. Mass balancing of PCL upon dermal and systemic administration
Treatment Dose applied (lg) SC (lg) ED (lg) LD (lg) Systemic (lg)
i.v. Taxol 1700 61.91 (3.64%) 82.92 (4.88%) 54.91 (3.23%) 235.3 (13.8%)
Dermal nanoemulsion 275 1.97 (0.72%) 4.35 (1.58%) 10.04 (3.64%) 0.61 (0.22%)
ED, epidermis; i.v., intravenous; LD, live dermis layers; PCL, paclitaxel; SC, stratum corneum.
All values are given in mg. Values in parenthesis indicate the percentage of administered drug localized in each compartment. In case of i.v. administration,
the remaining 74% drug is either eliminated or distributed into other tissues, whereas the unaccounted 94% drug upon dermal application is either
remaining in patch or eliminated from body. In case of i.v. administration, drug is distributed all over body, hence, for mass balancing purpose, surface area
of rat was taken as 233 cm2. However, in case of nanoemulsions, as is drug distributed in a local area of 4 cm2, calculations were performed for this area of
distribution. The amount of drug in systemic circulation was computed from Css,ave*Vd determined from i.v. dosing.
Upon i.v. administration, 11.7% of drug is distributed into skin tissues, 13.8% remained in plasma compartment, and remaining drug is distributed to other
tissues or eliminated from body. Whereas upon dermal administration, total formulation bioavailability was observed to be 6.2%, of which dermal
bioavailability was 5.95% and systemic bioavailability was mere 0.22%. This clearly indicates the skin localization of PCL with minimal systemic escape
until 48 h post-administration.
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by cetrimide, to an increased thermodynamic gradient
accomplished by the extraction of skin lipids. Gupta et al.
(2005) had attributed the skin permeation enhancement using
microemulsions to an interaction between microemulsion
components and the SC. In a comprehensive review on the
microemulsions role on skin permeation enhancement,
Kreilgaard (2002b) opined that the enhancement of drug
solubility plays the main role in skin permeation enhance-
ment of drugs from microemulsions. Once PCL has crossed
SC, owing to its inherent lipophilicity and high MW, it could
have moved slowly up to deeper subcutaneous layers, with
the aid of NE components. However, owing to lipophilic
nature of the drug, it is not efficiently taken up by systemic
circulation during the transit.
Even though formulation constituents were all approved
for dermal use at much higher levels than those utilized in the
formulations, it is essential to evaluate irritancy potential
when they are applied together in the form of formulation. In
addition, it also helps to rule out the probability of cumulative
toxicity. The visual scoring system adopted routinely for
irritancy tests is invariably associated with errors in subjective
evaluation. Therefore, in current investigation, irritancy
potential of formulation was assessed by using biophysical
tools transepidermal water loss (TEWL) and laser Doppler
velocimetry (LDV). Cutaneous irritancy is accompanied by
erythema and severe alteration of skin barrier function.
Erythema and inflammation are characterized by increased
blood flow, which is quantified by LDV. No statistically
significant difference was observed between before and after
treatment with formulation (P40.05), occlusion control, and
blank formulation (Figure 5a). Similarly, difference in TEWL
before and after treatment is statistically insignificant
(P40.05) (Figure 5b), indicating that the skin barrier function
is not altered irreversibly upon formulation application, and
formulations are safe and non-irritant when applied for
48 hours in vivo.
Conclusion
Owing to high MW, lipophilicity, and P-gp efflux, PCL is
difficult to deliver by oral and dermal routes. The combina-
tion of high lipophilicity and MW makes it an ideal candidate
to localize in skin layers upon dermal application. In this
investigation, pharmacokinetic proof is provided for the
localization of PCL in deep skin layers using novel NE
formulations. Further, using same NE formulation, peroral
bioavailability also was enhanced to above 70%, which is a
considerable enhancement over the previously reported
approaches. The dual achievement of selective localization
and systemic administration by changing route of adminis-
tration of same formulation can be favorably utilized for the
treatment of localized and systemically disseminated forms of
cancers and psoriasis.
MATERIALS AND METHODS
Animal ethics compliance and radioactive material handling
and disposal
The protocols for all the ex vivo and in vivo experiments performed
on Sprague–Dawley rats were approved by the Institutional Animal
Ethics Committee (IAEC, NIPER). The radioactive material was
handled in the premises approved for the purpose in accordance
with the statutory requirements of the Atomic Energy Regulatory
Board (AERB, GOI) and the biological waste was disposed according
to the IAEC, NIPER and AERB, GOI protocols.
Formulation of NEs
In case of formulation III, the drug (14C-PCL and PCL) was dispersed
in the internal oil phase (Labrafil, Gattefosse, France) by gentle
mixing. TPGS was dissolved in LSOL by warming to above 601C.
After cooling to room temperature, this surfactant mixture was added
to drug dispersion in oil. This forms the clear homogeneous
concentrate NE spontaneously. In case of blank NE (formulation I),
the oily phase was directly added to surfactant mixture. Formulation
II (Taxol) was prepared in the laboratory using the procedure and
formula reported previously (Gao et al., 2003).
Physical characterization of NEs
The developed NEs were characterized with respect to pH, globule
size distribution, zeta potential, and optical microscopy under
polarized light after diluting the concentrated NE (about 500ml) to
5 ml, 250 ml, and then to infinite dilution (more than 5 l). Globule size
distribution and zetapotential were measured using Zetasizer-Nano ZS
(Malvern, UK). The globule size distribution was measured by dynamic
light scattering, whereas zeta potential was measured by phase analysis
light scattering using mixed mode measurement (M3-PALS technique).
Polarized light microscopy was performed under cross-polarizers.
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Figure 5. The irritancy evaluation of NE formulation using biophysical tools.
(a) Skin local blood flow evaluation using LDV. (b) Skin barrier evaluation
using TEWL. Using both tools, no significant difference was observed
between naı¨ve rats and NE-treated rats (P40.05), indicating that formulation
is non-irritant and not altering barrier irreversibly in vivo.
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Globule size distribution and zeta potential measurement.
Globule size distribution and zeta potential were measured using
Zetasizer-Nano ZS fitted with 633 nm red laser. Both measurements
were performed simultaneously at various dilutions of same
concentrated NE sample, using folded capillary cell, at 251C, after
sufficient equilibration. For the purpose of measurement, the
dispersant was taken as water, and the refractive index of globules
were taken from reported values of oil (1.470). The measurement
was performed in triplicate and the parameters, z-ave size,
polydispersity index, were used as measures for the calculation of
mean size and size distribution, respectively. Before the measure-
ment of zeta potential of each sample, its pH was measured with a
pH meter using glass electrode (Thermo, Shield of Los Altos, CA).
Optical polarized light microscopy. As zetasizer can measure
globule size less than 10mm accurately, but in the presence of large
volume fractions of oil, it will give erroneous results. Moreover, it
cannot detect the presence of liquid crystalline phases. Hence, the
NEs were observed at various dilutions under polarized light
microscope. The samples were scanned at original magnification
 630 under cross-polarizers to observe any specific patterns
characteristic of liquid crystalline phases.
Evaluation of pharmacokinetic parameters of PCL in rats
Formulations of PCL administered in vivo, by various routes is given
in Table 1. In order to assess pharmacokinetic parameters of PCL in
Sprague–Dawley rats, commercial formulation, prepared in the
laboratory using a procedure described earlier (Gao et al., 2003),
was administered at same dose as that used for oral administration.
The animals were anesthetized using urethane (intraperitoneal,
1.6 g/kg), and the femoral vein was exposed at right thigh muscle.
A siliconized venous cannula was inserted, and after ligation using
the silk thread, formulation II (Table 1) containing 6.8 mg/g of PCL
was administered (10 mg/kg) slowly over 5 minutes, and then
cannula was withdrawn after ligating both ends of vein using silk
thread. The incision was sutured, after applying an anti-bacterial
dusting powder. A total of 200 ml of blood was withdrawn from retro-
orbital plexus at predetermined time points for 6 hours into
heparinized microcentrifuge tubes (50 IU/ml of blood) and plasma
was separated upon centrifugation at 2,000 g for 5 minutes. After
each sampling, 500ml of isotonic dextrose–normal saline solution
was administered intraperitoneally to provide nourishment and to
compensate for the depletion of fluid volume. The concentration of
drug was estimated by liquid scintillation counting.
Oral bioavailability assessment of formulation
Oral bioavailability assessment was performed in parallel groups of
six rats each. To one group, formulation I, containing 6.8 mg/g PCL,
was administered, and another group was administered with NE
(formulation III, containing 10 mg/g of PCL) (compositions given in
Table 1) by oral gavage (10 mg/kg). Blood was collected at
predetermined time points for 24 hours, then processed and
analyzed as described in previous section.
Dermal penetration and permeation of PCL from
NE formulation
Preparation of prototype patch. In order to facilitate application
of accurate dose and to control area of application, the NE was
applied after incorporating a weighed quantity of formulation into a
prototype patch of 4 cm2 area. The patch was prepared using a
procedure described previously (Panchagnula and Khandavilli,
2004b). Briefly, heat-sealable backing layer and microporous
polyethylene membrane were sealed on three sides, and after
incorporating a weighed quantity of formulation, the fourth side was
sealed. All patches were prepared 12 hours before application onto
animals. Before in vivo application, drug release from patch was
studied using rotating disk (USP 6) dissolution apparatus. Dissolution
was performed at 50 r.p.m., using 250 ml of ethanol:phosphate-
buffered saline (1:3) as dissolution medium, maintained at 321C in a
closed vessel. Samples were withdrawn intermittently (1 ml with
replacement) till 6 hours and released PCL was analyzed HPLC.
In vivo application of patch. After ensuring that drug release is
not controlled by patch using dissolution testing, the patches were
applied under occluded conditions on dorsal surface of animals and
the penetration and permeation of PCL was estimated for 48 hours.
Rats were anesthetized with urethane (1.6 g/kg, intraperitoneal),
and dorsal skin was shaven. Dermal administration was performed in
three groups, keeping blank and occlusion control for the purpose of
irritancy evaluation. Patches were affixed to the shaven dorsal skin
using medical grade adhesive tape. To one group, blank formulation
patch (formulation I, Table 1) was applied, and to another only the
patch was applied for assessing occlusion effect on skin. To another
parallel group, NE formulation patch (formulation II) was affixed.
Blood was collected into heparinized tubes from retro-orbital plexus,
which were processed similar to those samples obtained upon oral
and i.v. administration.
After experimentation, the skin exposed to formulation was
excised using scalpel after killing animal by cervical dislocation
while it is under anesthesia. Subcutaneous tissue attached to the
exposed skin was removed completely by scrapping with scalpel.
The excised fraction consists both the dermis and subcutaneous fatty
tissue. Upper tissue containing SC, live epidermis, and a part of
dermis was treated for 4 hours with 0.5% trypsin solution in
phosphate buffer (pH 8.0) absorbed on a filter paper. SC was then
carefully peeled off from the underlying epidermis and dermis layers.
Skin, by this process was, separated into three layers, SC, live
epidermis, and dermis together (denoted as epidermis in Discussion),
and subcutaneous tissue containing a part of dermis (denoted as LD).
Separated layers were subsequently dissolved in tissue solubilizer
and the amount of drug localized in each layer was quantified using
liquid scintillation counting.
Measurement of TEWL and LDV. In order to assess the irritancy
potential of NEs, two biophysical tools were employed. TEWL and
LDV were measured before and after the application of the patch in
all the three groups, that is, NE treatment, blank application, and
occlusion control.
TEWL measurement was performed by placing the collared probe
on the surface of dorsal skin of anesthetized rat. All measurements
were performed in a single ventilated room having controlled
temperature between 28 and 301C, and relative humidity of 38–40%.
Before measuring the local blood flow of skin using LDV, the
anesthetized animals were acclimatized to the room temperature
maintained at 251C for at least 1 hour. LDV measurement was
performed by applying the probe at 5 mm distance over skin. This is
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necessary to avoid any changes in local blood flow owing to the
pressure exerted by probe if directly contacted. The continuity
between skin and probe was maintained using normal saline drop in
between. Each measurement was performed for a minimum of
60 seconds.
Data processing and statistics
Pharmacokinetic parameters upon i.v. administration were calcu-
lated by fitting plasma concentration profile to two-compartment
model using PCNONLIN (version 4.0). AUC0t was calculated using
linear trapezoidal rule. AUCtN was estimated from the formula
Ct/Kel. Then, AUC0N was obtained by summation of these two com-
ponents. Absolute bioavailability was calculated by taking the ratio
of AUC0N obtained from dermal and oral routes with that obtained
upon i.v. administration. TEWL and LDV were compared before and
after treatment, and with that of occlusion and blank controls, using
t-test at 95% confidence interval. Skin affinity values for different
layers were reported per 4 cm2, the area of application of patch.
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